Niflunic acid

Manufactured by Merck Group

Sourced in Germany

Niflunic acid is a chemical compound that is used as a laboratory reagent. It serves as a precursor for the synthesis of various pharmaceutical and agrochemical products.

Automatically generated - may contain errors

Lab products found in correlation

Nifedipine, by Merck Group (3 mentions) Apamin, by Alomone (3 mentions) Chromanol 293b, by Merck Group (3 mentions) E 4031, by Merck Group (3 mentions) Dihydroouabain, by Merck Group (2 mentions) Nicl2, by Merck Group (2 mentions) Lidocaine, by Merck Group (2 mentions) Glibenclamide, by Merck Group (1 mentions) Disopyramide, by Merck Group (1 mentions) Ns8593, by Merck Group (1 mentions) Lipopolysaccharides (lps), by Merck Group (1 mentions)

3 protocols using niflunic acid

Pharmacological Modulation of hiPSC-CMs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Vernakalant was from Sigma-Aldrich (Taufkirchen, Germany). The drug was applied to a cell by a perfusion pipette, from low to high concentrations. The used concentrations were determined according to previous or our preliminary studies in hiPSC-CMs. E-4031, chromanol 293B, nifedipine, NiCl₂, glibenclamide, niflunic acid, lidocaine and dihydroouabain were from Sigma-Aldrich, 4-AP from RBI, apamin from Alomone Labs, tetrodotoxin (TTX) from Carl Roth (Karlsruhe, Germany). E-4031, NiCl₂, TTX, 4-AP, apamin, niflumic acid and dihydrooubain were dissolved in H₂O. nifedipine, and chromanol 293B were dissolved in DMSO, lidocaine in ethanol. Stock solutions were kept at −20 °C.

Xu Q., Huang X., Meng Z., Li Y., Zhong R., Li X., Cyganek L., El-Battrawy I., Akin I., Zhou X, & Lan H. (2022). Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. Journal of Cardiovascular Development and Disease, 9(4), 112.

+ Open protocol

+ Expand

Characterization of Cardiac Ion Channels

Check if the same lab product or an alternative is used in the 5 most similar protocols

Disopyramide is from SigmaAldrich. The drug was applied to a cell sequentially from low to high concentrations by a perfusion pipette. The tested concentrations were selected according to previous or our preliminary studies in hiPSC-CMs. E-4031, chromanol 293B, nifedipine, NiCl₂, niflunic acid, lidocaine, and dihydroouabain are from Sigma Aldrich, 4-AP from RBI, apamin from Alomone Labs, TTX from Carl Roth. E-4031, NiCl₂, TTX, 4-AP, apamin, niflumic acid, and dihydrooubain were dissolved in H₂O. nifedipine, and chromanol 293B were dissolved in DMSO, lidocaine in ethanol. Stock solutions were kept at -20 °C.

Lan H., Xu Q., El-Battrawy I., Zhong R., Li X., Lang S., Cyganek L., Borggrefe M., Zhou X, & Akin I. (2020). Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. Frontiers in Pharmacology, 11, 554422.

+ Open protocol

+ Expand

Electrophysiological Assay Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

E-4031, chromanol 293B, nifedipine, NiCl₂, NS8593, niflunic acid, LPS (Lipopolysaccharides from E. coli, source strain ATCC 12740, serotype 0127:B8, gel filtrated, gamma irradiated, cell culture tested, Sigma L 4516), lidocaine, glybenclamide and dihydroouabain are from Sigma Aldrich, 4-AP from RBI, apamin from Alomone Labs, TTX from Carl Roth. E-4031, NiCl₂, TTX, 4-AP, apamin, niflumic acid, glybenclamide and dihydrooubain were dissolved in H₂O. nifedipine, NS8593 and chromanol 293B were dissolved in DMSO, lidocaine in ethanol and LPS in RBMI medium. Stock solutions were kept at −20 °C.

Yücel G., Zhao Z., El-Battrawy I., Lan H., Lang S., Li X., Buljubasic F., Zimmermann W.H., Cyganek L., Utikal J., Ravens U., Wieland T., Borggrefe M., Zhou X.B, & Akin I. (2017). Lipopolysaccharides induced inflammatory responses and electrophysiological dysfunctions in human-induced pluripotent stem cell derived cardiomyocytes. Scientific Reports, 7, 2935.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!